

Warsaw, August, 2020

**Krzysztof LANDA, M.D.**



Current: President of MedInvest Scanner Ltd.

Former:

- ✓ Deputy Minister of Health of Republic of Poland
- ✓ Board Member of the National Center of Research & Development (NCBiR) of Republic of Poland
- ✓ Director of Drug Policy Department at the Central Office of the National Health Fund in Poland
- ✓ President of Watch Health Care Foundation
- ✓ General Partner and CEO in HTA Audit
- ✓ CEO in Meritum L.A.
- ✓ Partner in MedInvest Scanner
- ✓ Expert of BCC (Business Center Club) on health care systems
- ✓ President of HTA Consulting
- ✓ Member of Board of Directors Health Technology Assessment International (HTAi)
- ✓ President of Central & Eastern European Society of Technology Assessment in Health Care (CEESTAHC)
- ✓ Consultant in Dentons Business Services EMEA

Date of Birth: 26/08/1970

Nationality: Polish

## **Detailed Tasks Assigned:**

### Ministry of Health – ended in April 2017

- Basic Benefits Package (overseeing AOTMiT, the HTA Agency in Poland, AHTAPol)
- Drug Policy (overseeing Drug Policy & Pharmacy Department)
- Mapping of Health Needs (overseeing Department of Analysis & Strategy)
- Prices of health services (HTA Agency)
- Reimbursement and setting prices of medical devices and health procedures
- Investment in “heavy” health care facilities and medical devices (IOWISZ, the Instrument of Assessment of Investment Applications in Health Care)

### Dentons Business Services EMEA – ended in 2018

- CSR activities
- Consulting in market access, reimbursement & pricing
- Due diligence for M&A

### HTA Audit – ended in November 2015

- Co-directing the Firm
- Representation of the Firm
- Design & quality control of deliverables

### MedInvest Scanner

- Directing the Firm
- Representation of the Firm
- Supervision of development activities

### Watch Health Care Foundation

- Founder of Watch Health Care Foundation
- Representation of the Foundation
- Supervision over all activities of the Foundation

### Meritum L.A. – ended June 2020

- Directing the Firm
- Representation of the Firm
- Supervision over all activities of the Company
- Management of deliverables

### HTAi – ended June 2007

- Management of the Society – member of the Board of Directors
- Focus on the management of the HTAi Annual Meetings - member of the Annual Meetings Committee within the Board and since July 2006 the Chairman of this Committee
- Participation in Policy Forum

### CEESTAHC – ended June 2010

- International communication on behalf of CEESTAHC
- Search for and initializing of international projects run by CEESTAHC

- Supervision over international projects which CEESTAHC is involved with or led by the Society
- Supervision over PRS (Peer Review System; details on [www.ceestahc.org](http://www.ceestahc.org))

HTA Consulting – ended August 2006

- Development of HTA reports
- Leading educational courses on EBM, HTA, EBHC, pharmacoeconomics
- Systemic elaborations
- Market access strategies and consulting

## Key Qualifications:

### Professional Experience

Main projects and achievements in the Ministry of Health (MoH) in the period of 11.2015-04.2017:

- IOWISZ (Assessment Instrument for Healthcare Investment Applications, Polish: Instrument Oceny Wniosków Inwestycyjnych w Sektorze Zdrowia) – initiator, head of the implementing Team of “Mapmakers”; the provisions on IOWISZ have radically reduced the risk of the health need maps project and rationalised the spending of PLN 12 billion from the EU funds; IOWISZ applies also to the spending of national funds on large health care investments;
- Reimbursement Mode for Development (RTR, Polish: Refundacyjny Tryb Rozwojowy) – initiator, head of the interdepartmental team; RTR provides the criteria for the evaluation of drug manufacturers in Poland and their partnership with the Polish economy and a set of benefits available to companies doing business in Poland; a pro-investment project in the pharmacy area, included in the “major amendment to the Act on Reimbursement (DNUR)”;
- Reimbursement of Medical Devices (RWM) – the draft provisions on the reimbursement of medical devices were prepared in 2016 as part of the cooperation between Department of Drug Policy and Pharmacy (DPLiF) of the MoH, Agency for Health Technology Assessment and Tariff System (AOTMiT, Polish: Agencja Oceny Technologii Medycznych i Taryfikacji) and Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB, Polish: Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych); the project was suspended at the end of 2018 after its positive consideration by the Standing Committee of the Council of Ministers; the provisions would have allowed for the inclusion of medical device manufacturers in the RTR;
- Major amendment to the Act on Reimbursement (DNUR) – the project was suspended in September 2016 after a clearly positive outcome of the consensus conference; it included i.a.: The RTR, egalitarian approach to orphan drugs;
- Other projects: preparation and leading of the legislative process of provisions on free-of-charge pharmaceuticals available to senior citizens aged over 75 years, the so-called “75+ Act”, preparation of the draft provisions on emergency access to drug therapies (RDTL, Polish: Ustawa o Ratunkowym Dostępie do Technologii Lekowych) – amended after June 2016, major amendment of the Pharmaceutical Law (NOPEF, Polish: Duża Nowelizacja Prawa Farmaceutycznego) in connection with the new “Pharmacies for pharmacists” amendment (AdA, Polish: Apteka dla Aptekarza), reduction of valuations in interventional

cardiology with a balanced increase in valuation in many other underfinanced areas of the Polish health care system, draft provisions on registries, draft provisions on the profession of pharmacist, project of the Rare Disease Plan (completed in January 2017), project of the National Drug Policy (completed in January 2017), completion of the first health need maps in Poland, obtaining funds to employ 100 analysts at the AOTMIT to work on the guaranteed benefits package, initiation of works on the content of the package in cooperation with the NHF, change of tariffs for numerous health care services, numerous reimbursement decisions – the greatest success being the reimbursement of many new molecules on the list published on 1.07.2016 with the expected reduction of expenditure on pharmaceuticals; many others;

Director of the Pharmaceutical Management Department (Polish: Departament Gospodarki Lekami) of the NHF Central Office

- Order of the President of the NHF No. 17/2007 – the first legal instrument in Poland to regulate the reimbursement of drugs in accordance with the requirements of the EU Transparency Directive; it concerned the launch of new therapeutic programmes/drug programmes covering very expensive pharmaceuticals used in rare and ultrarare indications;
- Creating catalogues of new drug programme reimbursement applications which at that time were submitted to the NHF Central Office;
- Creating rankings of new drug programme reimbursement applications;
- Participation in the works of the Consultation Board (currently: The Transparency Council) of the President of the Agency for Health Technology Assessment;
- Participation in the works of the Drug Management Team (currently: Economic Commission) of the Minister of Health;
- Project of visiting and strengthening Drug Management Divisions (WGL, Polish: Wydziały Gospodarki Lekami) in Regional Offices of the NHF across the entire territory of Poland “by turns”;
- Enhancing capacities of drug prescription controls and launching the first fraud detection team in Poland.

<b>Date from - Date to</b>	<b>Location</b>	<b>Degree of Responsibility</b>
Since 2020	POLAND	Workshops & consulting in Evidence-Based PR (public relations) and bridging HTA
August 2017 – April 2018	POLAND	Consultations in MA, due diligence in M&A, CSR in Dentons
November 2015 – April 2017	POLAND	Deputy Minister of Health: drug policy, reimbursement and prices of medical devices, mapping of health needs, investments in health care, prices of health services, basic benefits package
January 2013 – October 2014	UKRAINE	TEAM LEADER – capacity building in EBM & HTA in Ukraine; in-depth training of 12 persons from public & private institutions; awarded the “Panacea” Prize of the Best Project in Health Care in Ukraine in 2013.

September 2007- April 2008	SERBIA	TEAM LEADER – consultancy for the Serbian Ministry of Health in respect to evidence based Basic Benefit Package (BBP), design and feasibility study on different models of HTA Agency in Serbia, quality of practice guidelines
2007-2015	POLAND	CEO and President of HTA Audit – audits and quality control of over 100 HTA reports and pharmacoeconomic studies
October 2006 – August 2007	POLAND	DIRECTOR of Drug Policy Department of National Health Fund (NHF) in Poland – therapeutic programs with ranking based mostly on cost-effectiveness ratios, catalog of chemotherapy regimens, direct import of drugs, fraud detection & fraud prevention, drugs utilization reporting systems of the fund; monitoring of medical prescribing; NHF member of Drug Reimbursement Committee at the Minister of Health; NHF member of Consultancy Council at the Polish HTA Agency
June 2006- January 2007	SERBIA	HTA EXPERT - consultancy for the Serbian Ministry of Health in respect to EBHC development and HTA systemic implementation. In-depth training of Serbian HTA analysts and development of 3 country specific HTA reports were key responsibilities of Krzysztof Landa
2006	POLAND	PROJECT LEADER - two significant publications: "Basic features and principles of benefit packages development in selected countries" and "Inclusion and exclusion criteria for basic benefit packages in selected countries – recommendations for Poland".
2000-2006	POLAND	TEAM LEADER – development of over 80 full HTA reports on drug and non-drug medical technologies; HTAs based on systematic reviews and including comparative economic evaluations (CM, CE, CU, CB, CC) and financial analyses (Budget Impact type)
1999-2001	POLAND	TEAM LEADER - as the Head of Bureau for the Standardization of Medical Practice in governmental institution NCQA development of 7 evidence-based practice guidelines. Among other: Evidence-Based Practice Guidelines for COPD Management in Primary Care – September 2001 and Evidence-Based Practice Guidelines for Chronic Pain Management in Primary Care – June 2001. Advanced works on CPGs in depression, stroke, CHD, asthma, hypertension. All CPGs were evidence based and developed with close cooperation with all medical associations interested in the topic; all recommendations were marked due to quality of evidence and strength of intervention.
2000-2001	POLAND	TEAM LEADER – development of methodology, structure and initial assignments to Basic Benefit Package (BBP) in Poland (project financed by the World Bank in cooperation with Dutch TNO); personal responsibility of the component 6 in the project devoted to BBP resulted with co-authorship of the report with Prof. David Banta
2003-2010	POLAND Centre for Public Health of the Leon Kozminski Academy of Entrepreneurship and Management in WARSAW	Lectures on 4 main subjects in postgraduate educational program at university level: Pharmacoeconomics, Non-drug Technology Assessment, Use of Medical and Economic Data Bases, Evidence-Based Medicine (EBM) / Clinical Epidemiology
Since 1998	POLAND	TEAM LEADER – management and teaching in various (for about 2000 participants) educational programs on Evidence-Based Medicine (EBM) and Health Technology Assessment (HTA)
2000-2001	EU	Project member - European Collaboration for Health Technology Assessment (ECHTA / ECAHI); project financed by European Commission
2000	Council of Europe	Participation in elaboration of Guidelines for Recommendations Development of the Council of Europe
1998-1999	POLAND	Project member – 2 CPGs (asthma, hypertension) based on consensus reached by Delphi method; organized by Collegium of Primary Care Physicians.

November 2002 and November 2003	CROATIA (+ many more presentations and lecturers on Evidence-Based Health Care in many countries since 1999)	“HTA in Poland – education, expertise and its use” and “HTA in reimbursement policy – examples of real impact” at the 6th International HIT conference: biotechnology and public health” in Cavtat
---------------------------------	-----------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Trainings

<b>Institution [Date from : Date to]</b>	<b>Degree or Diploma obtained:</b>
Various educational courses in the area of EBHC [1996]	Various diplomas / among the other from: “Oxford Workshop in Teaching Evidence Based Medicine” in 1999 led by Prof. David Sackett
Harvard-Jagiellonian Consortium for Health [1997:1998]	-
Assistant of the Director of HMO-like organization in Krakow “SP ZOZ Krowdrza” [1998]	-

## Education:

<b>Institution [Date from : Date to]</b>	<b>Degree or Diploma obtained:</b>
University School of Medicine in Lublin, Poland [19989-1996]	Medical Doctor
Postgraduate School of Public Health of Jagiellonian University in Krakow, Poland; Faculty: Management and Administration in Public Health.	Certificate of program completion

## Employment Record:

<b>Date from - date to</b>	<b>Location</b>	<b>Company</b>	<b>Position</b>	<b>Description</b>
November 2015 – April 2017	Warsaw, Poland	<b>Ministry of Health</b>	Deputy Minister of Health	Drug policy, reimbursement and prices of medical devices, mapping of health needs, investments in health care, prices of health services, basic benefits package
September 2014 – still ongoing	Krakow, Poland	<b>MedInvest Scanner Ltd.</b>	President	Development & representation of the company which decreases investment risks in health technologies for various parties and due diligence with respect to product evaluation
2011-June 2020	Krakow, Warsaw, Poland	<b>Meritum L.A. Ltd.</b>	President	Actuarial works, modelling for complementary policies and development of actuarial reports for complementary health insurance

<b>Date from - date to</b>	<b>Location</b>	<b>Company</b>	<b>Position</b>	<b>Description</b>
April 2010 – November 2015	Krakow, Poland	<b>Watch Health Care Foundation</b>	Founder, President of the Board	Indicating fields of inequalities regarding the access to health benefits; Defining ways of changing the negative state of play regarding the access to health benefits in compliance with HTA principles; Promoting the most clinically-effective, safe and cost-effective health technologies which marry with the limited financial capacity of the State in order to make them generally accessible to society; Promoting the idea of an additional health insurance as a form of supplementing the system of compulsory insurances, supporting the initiative aiming at developing the market of compulsory and voluntary insurances;
October 2007 – November 2015	Krakow, Poland	<b>HTA Audit</b>	President, Senior Consultant	Quality control of HTA reports, systematic reviews, economic evaluations and budget impact analyses, risk sharing agreements, pricing
2005 - September 2007	Beograd, Serbia	<b>MoH</b>	Team Leader	Project on improving parts of Basic Benefit Package (BBP) in Serbia based on best practice from the world, design of and feasibility study on different models of HTA Agency in Serbia, quality management of clinical practice guidelines
October 2006 – August 2007	Warsaw, Poland	<b>National Insurance Fund</b>	Director of Drug Policy Department	Reimbursed drugs, drug therapeutic programs, chemotherapy regiments catalogue, overseeing and use of data from the Fund reporting systems; <a href="http://www.nfz.gov.pl">www.nfz.gov.pl</a>
June 2007 – December 2007	Beograd, Serbia	<b>MoH</b>	HTA Leader	Project on EBHC introduction to Serbia. Responsibility for education in respect to EBM, HTA, FE, information management etc. Elaboration of 3 HTA reports on the topics selected by the Minister of Health.
Nov 2001- September 2006	Krakow, Poland	<b>HTA Consulting</b>	Chief Executive Officer	Development of HTA reports for industry and public health insurance – about 70 full HTA reports and financial analyses developed since 2001 (some in Polish and in English can be found on <a href="http://www.hta.pl">www.hta.pl</a> / reports). Organization and running Evidence-Based Medicine (EBM) and Health Technology Assessment (HTA) educational and promotion programs (details on Polish site <a href="http://www.hta.pl/szkolenia">www.hta.pl/szkolenia</a> ). The company organizes 1-5 day workshops on EBM and HTA but also pharmacoeconomics, use of data bases, reimbursement systems in the world (including area of basic benefit packages, models of HTA Agencies, reimbursement lists and criteria of inclusions and exclusions). Such workshops are organized on request mostly from the pharmaceutical and devices industry ( <a href="http://www.hta.pl/klienci">www.hta.pl/klienci</a> ) but also for public Sick Funds (National Health Insurance).
August 2003 – September 2006	Krakow, Poland	<b>Central &amp; Eastern European Society of Technology Assessment in Health Care</b>	Former Vice-President; funding member; Director of International Projects	Development and promotion of regulations, methods and experience associated with evaluations of drugs and non-drug technologies in Central & Eastern European countries; Estimation of quality of economic and financial evaluations in health care; Education and training in EBM, HTA, pharmacoeconomics, medical and economic databases, systematic reviews and systemic towards EBHC.
October 2002 – 2006	Warsaw, Poland	Centre for Public Health of the Leon Kozminski Academy of Entrepreneurship and Management	Adjunct Professor	Lectures on 4 main subjects in postgraduate educational program at university level: Pharmacoeconomics, Non-drug Technology Assessment, Use of Medical and Economic Data Bases, Evidence-Based Medicine (EBM) / Clinical Epidemiology. The lecture hours of the four key subjects sum up in 92. The program is focused on building knowledge, skills and attitude of the about 20-25 students of each edition. In February 2006 the fourth edition begins.

Date from - date to	Location	Company	Position	Description
1999 - continuing	CROATIA (Nov 2002 and Nov 2003) UK, BELGIUM, ITALY, AUSTRIA, CANADA, GERMANY, SWEDEN, SWITZERLAND, CZECH REP.	Various organizations, companies and institutions in different countries, in Croatia Ministry of Health and International Scientific Program Committee of HIT Conference	Lecturer	<p>Approximately 5 abroad lectures a year: 2 lectures in Croatia highlighted Presentations in Croatia were aimed to help establish HTA Agency, develop Basic Benefit Package and implement EBHC on invitation from the authorities: "HTA in Poland – education, expertise and its use" in Belgrade (1 hour) and "HTA in reimbursement policy – examples of real impact" (1 hour) at the 6th International HIT conference: biotechnology and public health" in Cavtat</p> <p>Other presentations were aimed to promote HTA, EBM and EBHC with special focus on various models of HTA governmental agencies functioning, establishment of transparent criteria of reimbursement decision-making and methods of HTA as well as clinical practice guidelines development and implementation</p> <p>Other examples: "HTA as a basic tool for rational decision making and prioritization", "Basic Benefit Package", "HTA and policy-making: considerations based on the Polish experience", "Mutual Peer Review System – MPRS", "A view on: Improving the performance of Health Systems in the enlarged EU, and possibilities of effective interventions in the field of avoidable mortality", "Inevitable marketing changes due to HTA - analytical challenges in Poland", "A Comparison of the Efficacy, Safety and Cost-Effectiveness of Rapamycin-Eluting Stent with Invasive Cardiology Methods Commonly Used in Poland in the Treatment of Ischaemic Heart Disease", "Health Technology Assessment and Practice Guidelines in Polish Health Care System", "HTA in CEE Countries – Poland", "Priority setting in health care policy: how should rare diseases be treated due to limited resources".</p> <p>Many conference presentations and workshops (from 1 hour to 5 days) in Poland.</p>
Jan 2000- Feb 2006	Poland	<b>NCQA and HTA Consulting</b>	Team Leader	<p>Development of over 80 full HTA reports based on systematic reviews, comparative economic evaluations and budget impact analyses. Few examples:</p> <ol style="list-style-type: none"> <li>1. A Comparison of the Efficacy and Cost-Effectiveness of Selected Treatment Methods for Hemorrhoids – 2001</li> <li>2. An Efficacy Analysis of Interferon B in Treatment of Sclerosis Multiplex – 2001</li> <li>3. A Comparison of the Efficacy and Cost-Effectiveness of Hip and Knee Prostheses for Arthroplasty - 2001</li> <li>4. A Comparison of Manual and Automatic Methods for Decontamination of Flexible Endoscopes - 2001</li> <li>5. A Comparison of the Efficacy and Cost-Effectiveness of Prolene Hernia System (PHS) with Other Popular Surgical Methods of Inguinal Hernia Treatment - 2001</li> <li>6. Percutaneous Core Breast Biopsy Methods for Nonpalpable Breast Lesions Diagnosis- 2001</li> <li>7. A Comparison of the Efficacy and Cost-Effectiveness of the Most Popular Urinary Incontinence Treatment Methods - 2001</li> <li>8. A Comparison of the Efficacy and Cost-Effectiveness of Rapamycin-Eluting Stent with Invasive Cardiology Methods Commonly Used in Poland in the Treatment of Ischemic Heart Disease – 2002</li> <li>9. A Comparative Cost-Effectiveness Analysis of Entacapone in the Therapy of Parkinson Disease</li> <li>10. A Comparison of the Efficacy and Cost-Effectiveness of Invasive and Pharmacological Methods in the Therapy of Cardiac Arrhythmias – 2002</li> <li>11. A Comparative Efficacy Analysis of Lamivudine and Selected Options in the Therapy of Hepatitis B - 2002</li> </ol> <p>Other cannot be listed here due to the contractors requirements or are available in full text on <a href="http://www.hta.pl">www.hta.pl</a> / reports.</p>



Date from - date to	Location	Company	Position	Description
1998-2001	Krakow, Poland	<b>National Center for Quality Assessment in Health Care (NCQA) – governmental agency</b>	Head of the Bureau for the Standardization of Medical Practice	The Bureau consisted of 3 Teams for: Practice Guidelines Development, HTA and Team Affiliated with Nordic Cochrane Center). Basic Benefit Package elaboration in 2001 with Dutch TNO. Since November 1998, leading national 4-day EBM courses for Polish doctors and decision-makers and 5-day courses for EBM tutors. Introduction of EBM to Medical University School of Bydgoszcz. Cooperation with Polish Ministry of Health in development of evidence-based practice guidelines and standards for contracting with Sick Funds; HTA for public and private sector.
1997-1998	Krakow, Poland	<b>Harvard-Jagiellonian Consortium for Health</b>	Consultant and trainee	Consultancy for public sector in respect to: practice guidelines (CPGs), practice standards, disease management (DM), diagnosis related groups (DRGs). On the assignment and in cooperation with Polish politicians collecting knowledge and experience from other countries in the listed topics. Preparatory works on legislative acts. Responding to inquires from local governments and health care providers. Publishing articles, co-authorship in a book "Management of Health Care in Local Governments".

### Important publications:

“Cancer Drug Fund in Poland – proposition of systemic arrangements” [Fundusz Walski z Rakiem (FWR) – propozycje rozwiązań systemowych]; Krakow/Warszawa 2016.

„Health insurance & basic benefits package – review of possible systemic arrangements”;  
„Ubezpieczenia zdrowotne a koszyki świadczeń - przegląd rozwiązań”; CEESTAHC 2011.

“PRICING. Prices of reimbursed drugs, negotiations and risk sharing” 2009; the main author & leader of co-authors team; large parts available in English translation on: <http://tinyurl.com/kqw69sy>.

„Features & principles of management of basic benefits packages in selected countries”;  
Podstawowe cechy i zasady tworzenia koszyków świadczeń zdrowotnych w wybranych krajach” Łanda, Władysiuk-Blicharz, Nadzieja, Gąsiorowski, Dziadyk; HTA Consulting, Kraków 2006.

„Kryteria włączania i wykluczania z koszyka świadczeń gwarantowanych w wybranych krajach - możliwości wykorzystania w Polsce” Łanda, Nadzieja, Plisko, Władysiuk-Blicharz, Ryś, Siwiec, Gąsiorowski; CEESTAHC, Kraków 2006; opublikowane na [www.aotm.gov.pl](http://www.aotm.gov.pl).

„Standardy świadczeń zdrowotnych nabywanych w ramach systemu opieki zdrowotnej w Polsce”; 7 komponentów – osobiste kierownictwo prac w ramach komponentu 6 dotyczącego zasad tworzenia koszyka świadczeń; we współpracy z holenderskim TNO i Prof. Davidem Banta; 2000-2001.

„Priorytety zdrowotne – narzędzia oceny i analizy”; współautorstwo i kierownictwo prac 2 części: „Analizy efektywności” oraz „Analizy opłacalności”; Wydawnictwo Medyczne „Vesalius”; 2002.

“Zarządzanie Opieką Zdrowotną w Powiecie” z Prof. Cezarym Włodarczykiem i Dr Stojniewem Sitko; grudzień 1998; wydany przez Powiatowe Konsorcjum Konsultingowe.

„Ocena wpływu instytucji regulatora publicznego na proces kształtowania cen leków na rynkach wybranych krajów świata” – wrzesień 2005; współautor raportu badawczego WSPiZ opracowanego na zlecenie SPFF w Polsce.

**Languages:**

<b>Language</b>	<b>Reading</b>	<b>Speaking</b>	<b>Writing</b>
Polish	Mother tongue		
English	excellent	excellent	excellent
Russian	fair	poor	fair

A handwritten signature in blue ink, appearing to be 'H. Gawron', written over a horizontal line.

Date: 08/2020  
Month/Year